Inventiva to present new lanifibranor Phase 3 NATiV3 MASH trial data in Q4 update, AASLD abstracts show
IVA•Inventiva said three scientific posters on lanifibranor for MASH will be presented at AASLD The Liver Meeting 2026. Topline results from the Phase 3 NATiV3 trial are expected in the fourth quarter of this year.
1. Posters and trial update
Inventiva announced three scientific posters on lanifibranor for MASH will be presented at AASLD The Liver Meeting 2026. The company said new preclinical analyses indicate the drug acts across multiple liver cell types, while other analyses point to improvements in endothelial dysfunction and coordinated epigenetic disruption across PPAR pathways; NATiV3 topline results are expected in the fourth quarter.
